Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed up to 24% weight loss in phase 2 trials
C.Van GaalL.et al (2017)
It helps regulate blood glucose by enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and promoting satiety
Although speculative, we assume that after short exposure of artery to hyperglycemia and/or hypercholesterolemia, GLP-1 receptor increases to protect artery initially, but that after chronic exposure to them, such protective pathway does not appropriately function
If a needle-free format matters to you, PlexusDx offers Semaglutide Oral and the Microdose GLP-1 Protocol with four delivery variants, but injection remains the most evidence-supported delivery format for weight loss